NO20064510L - Oral mosidomin sammensetning med vedvarende frigjoring - Google Patents

Oral mosidomin sammensetning med vedvarende frigjoring

Info

Publication number
NO20064510L
NO20064510L NO20064510A NO20064510A NO20064510L NO 20064510 L NO20064510 L NO 20064510L NO 20064510 A NO20064510 A NO 20064510A NO 20064510 A NO20064510 A NO 20064510A NO 20064510 L NO20064510 L NO 20064510L
Authority
NO
Norway
Prior art keywords
composition
mosidomin
oral
sustained release
molsidomin
Prior art date
Application number
NO20064510A
Other languages
English (en)
Other versions
NO336913B1 (no
Inventor
Jozsef-Michel Geczy
Original Assignee
Therabel Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Therabel Pharmaceuticals Ltd filed Critical Therabel Pharmaceuticals Ltd
Publication of NO20064510L publication Critical patent/NO20064510L/no
Publication of NO336913B1 publication Critical patent/NO336913B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Anvendelse av molsidomin eller ett av dets farmasøytisk akseptable salter, som er anvendelige innen den farmasøytiske industri, spesielt i form av en peroral fast sammensetning med vedvarende frigjøring med effekt i 24 timer, for fremstilling av et medikament til forhindring eller reduksjon av utviklingen av aterosklerose.
NO20064510A 2004-04-05 2006-10-04 Anvendelse av molsidomin eller ett av dets farmasøytisk akseptable salter, i form av en oral fast sammensetning NO336913B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0403534A FR2868314B1 (fr) 2004-04-05 2004-04-05 Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
PCT/EP2005/003531 WO2005107761A1 (fr) 2004-04-05 2005-04-01 Composition orale de la molsidomine a liberation prolongee pour le traitement de l’atherosclerose

Publications (2)

Publication Number Publication Date
NO20064510L true NO20064510L (no) 2006-10-31
NO336913B1 NO336913B1 (no) 2015-11-23

Family

ID=34944920

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064510A NO336913B1 (no) 2004-04-05 2006-10-04 Anvendelse av molsidomin eller ett av dets farmasøytisk akseptable salter, i form av en oral fast sammensetning

Country Status (29)

Country Link
US (1) US7754715B2 (no)
EP (1) EP1732565B8 (no)
JP (1) JP5117847B2 (no)
KR (1) KR101162385B1 (no)
CN (1) CN1938032B (no)
AU (1) AU2005239799B2 (no)
BE (1) BE1016580A3 (no)
BR (1) BRPI0509642A (no)
CA (1) CA2562287C (no)
CY (1) CY1117614T1 (no)
DK (1) DK1732565T3 (no)
ES (1) ES2567576T3 (no)
FR (1) FR2868314B1 (no)
HK (1) HK1092736A1 (no)
HR (1) HRP20160479T1 (no)
HU (1) HUE029199T2 (no)
IL (1) IL178440A0 (no)
IT (1) ITTO20050220A1 (no)
MA (1) MA28518B1 (no)
MD (1) MD4080C1 (no)
NO (1) NO336913B1 (no)
NZ (1) NZ550341A (no)
PL (1) PL1732565T3 (no)
RS (1) RS54791B1 (no)
RU (1) RU2388475C2 (no)
SI (1) SI1732565T1 (no)
UA (1) UA88461C2 (no)
WO (1) WO2005107761A1 (no)
ZA (1) ZA200608219B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE033092T2 (hu) * 2012-05-31 2017-11-28 G Pohl-Boskamp Gmbh & Co Kg Arteriogenezis indukálása nitroglicerinnel mint nitrogén-oxid donorral

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385937A (en) * 1991-04-10 1995-01-31 Brigham & Women's Hospital Nitrosation of homocysteine as a method for treating homocysteinemia
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
US6472390B1 (en) * 2001-11-13 2002-10-29 Duke University Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
KR100464876B1 (ko) * 2001-11-15 2005-01-06 학교법인 인제학원 동충하초의 코르디세핀을 함유하는 항혈전제 조성물
WO2010062256A1 (en) * 2008-11-27 2010-06-03 Nanyang Polytechnic Process and system for automatic identification of the larvae of aedes albopictus and aedes aegypti

Also Published As

Publication number Publication date
CA2562287C (fr) 2013-05-14
DK1732565T3 (en) 2016-05-09
US7754715B2 (en) 2010-07-13
CN1938032A (zh) 2007-03-28
BE1016580A3 (fr) 2007-02-06
ZA200608219B (en) 2008-02-27
MD4080C1 (ro) 2011-07-31
WO2005107761A1 (fr) 2005-11-17
NO336913B1 (no) 2015-11-23
AU2005239799B2 (en) 2010-12-23
EP1732565B1 (fr) 2016-03-09
FR2868314A1 (fr) 2005-10-07
CN1938032B (zh) 2010-06-09
ES2567576T3 (es) 2016-04-25
SI1732565T1 (sl) 2016-06-30
MA28518B1 (fr) 2007-04-03
EP1732565B8 (fr) 2016-05-11
EP1732565A1 (fr) 2006-12-20
FR2868314B1 (fr) 2008-10-24
JP2007531781A (ja) 2007-11-08
HK1092736A1 (zh) 2007-02-16
UA88461C2 (ru) 2009-10-26
RS54791B1 (sr) 2016-10-31
NZ550341A (en) 2009-11-27
KR101162385B1 (ko) 2012-07-06
MD4080B1 (en) 2010-12-31
CY1117614T1 (el) 2017-04-26
HRP20160479T1 (hr) 2016-06-03
PL1732565T3 (pl) 2016-08-31
RU2388475C2 (ru) 2010-05-10
BRPI0509642A (pt) 2007-09-18
CA2562287A1 (fr) 2005-11-17
AU2005239799A1 (en) 2005-11-17
RU2006134695A (ru) 2008-05-20
JP5117847B2 (ja) 2013-01-16
HUE029199T2 (en) 2017-03-28
ITTO20050220A1 (it) 2005-10-06
KR20070015534A (ko) 2007-02-05
IL178440A0 (en) 2007-02-11
US20070212413A1 (en) 2007-09-13

Similar Documents

Publication Publication Date Title
CU23551B7 (es) Procedimiento para la producción de una composición farmacéutica sólida de administración oral
WO2006127738A3 (en) Compressible chewing gums for delivery of actives
ZA200704163B (en) Oral medicament for the modified release of at least one active principle, in a multimicrocapsule form
GEP20084468B (en) Gamma-d crystalline form of ivabradin hydrochloride, process for its preparation and pharmaceutical compositions containing it
UA86622C2 (ru) Фармацевтическая композиция, которая диспергируется в ротовой полости, для введения в слизистую оболочку ротовой полости или подъязычного введения агомелатина
NO20051389L (no) Stabilisert farmasoytisk blanding inneholdende basiske hjelpemidler
MX2010003989A (es) Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
ECSP055568A (es) Composición de comprimido de liberación sostenida de pramipexol
ATE397605T1 (de) Nebivolol und dessen pharmazeutisch unbedenkliche salze, herstellungsverfahren und pharmazeutische zusammensetzungen von nebivolol
NO20084065L (no) Hurtig frigivelses paracetamol tabletter
ATE533476T1 (de) Komprimierte pharmazeutische zusammensetzung mit beschichteten pellets und direktes kompressionsgemisch und herstellungsverfahren dafür
AR054129A1 (es) Derivados de 2, 6-quinolinilo, una preparacion farmaceutica que los contiene y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades dependientes de integrinas alfa4beta1 y/o alfa4beta7
NO20062491L (no) Benzoksazinderivter og deres anvendelse
DK1467724T3 (da) Farmaceutisk sammensætning med agomelatin til dispergering i mundhulen
NO20073551L (no) Nikotinacetylkolinreseptorligander
NO20050771L (no) Bicifadinformulering
TNSN07337A1 (en) Pharmaceutical composition comprising an indolylmaleimide derivative
DK1511489T3 (da) Nye farmaceutiske sammensætninger indeholdende flibanserin-polymorf A
NO20064808L (no) Orale matrixformuleringer med licarbazepin
EA200001201A2 (ru) Таблетка с основой, позволяющая осуществлять пролонгированное высвобождение триметазидина после введения оральным путем
EA200500213A1 (ru) Диспергируемые таблетки для орального назначения
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
EA200600953A1 (ru) Дозированные формы торсемида пролонгированного высвобождения
RS51534B (en) NEW COMPOUND OF SINUSOID IF CURRENT INHIBITORS AND CALCIUM INHIBITOR AND PHARMACEUTICAL MIXTURE CONTAINED BY IT
NO20064510L (no) Oral mosidomin sammensetning med vedvarende frigjoring